Tegafur,Gimeracil and Oteracil Potassium

Treatment with camrelizumab, rivoceranib, and chemotherapy (SOXRC) showed better pre- and postsurgical responses in advanced gastric cancer compared to chemotherapy alone (SOX). The phase 3 DRAGON IV/CAP 05 study reported pathologic complete response rates of 18.3% vs. 5% and major pathologic response rates of 51.1% vs. 37.8% in the SOXRC and SOX groups, respectively. The study suggests an early signal of efficacy for combined PD-1/VEGFR inhibition plus chemotherapy, though not yet ready for routine use.

HUTCHMED announces new data from the sovleplenib ESLIM-01 Phase III trial and several investigator-initiated studies will be presented at the 2024 ASH Annual Meeting and ESMO Asia Congress. Long-term safety and efficacy data from the ESLIM-01 sub-study showed sovleplenib effectively increased and maintained platelet count in chronic primary ITP patients, with a well-tolerated safety profile.